OpenAI Eyes Pharma Gold Rush With AI Drug Discovery Plans
OpenAI CEO Sam Altman revealed ambitious plans to enter pharmaceutical research, proposing a novel funding model where the AI giant could subsidize drug development costs in exchange for future royalties. Speaking at a San Francisco tech conference, Altman positioned this as mutually beneficial - advancing medical science while creating new revenue streams. While no deals are finalized, the move signals OpenAI's growing appetite for commercializing its AI beyond traditional tech applications.